Anemia, fatigue and aging;Anémie, épuisement et vieillissement

Transfusion Clinique et Biologique

Volumn 17, Issue 5-6, 2010, Pages 375-381

  Balducci, L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Aging; Anemia; Cancer; Fatigue

Indexed keywords

CYTOTOXIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TESTOSTERONE;

AGING; ANEMIA; BLEEDING; CANCER PATIENT; COPPER DEFICIENCY; DAILY LIFE ACTIVITY; DEMENTIA; FALLING; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INCIDENCE; INFLAMMATION; IRON DEFICIENCY; KIDNEY FAILURE; MALABSORPTION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MUSCLE ATROPHY; MYELODYSPLASTIC SYNDROME; PREVALENCE; QUALITY OF LIFE; RISK FACTOR; SEX DIFFERENCE; SHORT SURVEY;

ACTIVITIES OF DAILY LIVING; AGE OF ONSET; AGED; AGED, 80 AND OVER; AGING; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; COGNITION DISORDERS; COMBINED MODALITY THERAPY; COMORBIDITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEMATINICS; HEMOGLOBINS; HUMANS; INFLAMMATION; MALABSORPTION SYNDROMES; MALE; NEOPLASMS; VENOUS THROMBOSIS;

EID: 78649629716     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2010.09.169     Document Type: Short Survey

References (92)

1. Yancik R., Ries L.A. Cancer in the older person: an International issue in an aging world. Sem Oncol 2004, 31:128-136.
2. Guralnick J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., Woodman R.C. Prevalence of anemia in persons 65 year and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2063-2068.
3. Ferrucci L., Balducci L. Anemia of aging: role of chronic inflammation and cancer. Semin Hematol 2008, 45:242-249.
4. Walston J., Hadley E.C., Ferrucci L., Guralnik J.M., Newman A.B., Studenski S.A., et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Ger Soc 2006, 54:991-2001.
5. Gruenewald TL, Seeman TE, Karlamangla AS, Sarkisian CA. Allostatic load and frailty in older individuals. J Am Geriatr Soc 2009;57(9):1525-31 [Epub 2009 Jul 21].
6. Anisimov V.N., Egormin P.A., Piskunova T.S., Popovich I.G., Tyndyk M.L., Yurova M.N., et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010, 9(1):188-197.
7. Coppé J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010, 5:99-118. Review.
8. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010;29(2):273-83.
9. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory network during senescence: causes and consequences. Trends Mol Med 2010;16(5):238-46.
10. Stirewalt D.L., Mhyre A.J., Marcondes M., Pogosova-Agadjanyan E., Abbasi N., Radich J.P., et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS. Br J Haematol 2008, 140(4):444-453.
11. Willeit P., Willeit J., Mayr A., Weger S., Oberhollenzer F., Brandstätter A., et al. Telomere length and incident cancer and cancer mortality. JAMA 2010, 304:69-75.
12. Wong L.S., van der Harst P., de Boer R.A., Huzen J., van Gilst W.H., van Veldhuisen D.J. Aging, telomeres, and heart failure. Heart Fail Rev 2010, 15(5):479-486.
13. Willeit P, Willeit J, Brandstätter A, Ehrlenbach S, Mayr A, Gasperi A, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2010;30(8):1649-56.
14. Sahin E., Depinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464(7288):520-528.
15. Babizhayev MA, Savel'yeva EL, Moskvina SN, Yegorov YE. Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther 2010. doi:10.1097/MJT.0b013e3181cf8ebb.
16. Risques R.A., Arbeev K.G., Yashin A.I., Ukraintseva S.V., Martin G.M., Rabinovitch P.S., et al. Leukocyte telomere length is associated with disability in the older USA population. J Am Ger Soc 2010, 58:1289-1298.
17. Shiels P.G. Improves precision in investigating aging: why telomeres can cause problems. J Gerontol Biol Sc 2010, 65A:789-791.
18. Ferrucci L., Corsi A., Lauretani F., Bandinelli S., Bartali B., Taub D.D., et al. The origin of age-related pro-inflammatory state. Blood 2005, 105:2294-2299.
19. Maggio M., Guralnik J.M., Longo D.L., Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006, 61(6):575-584.
20. Crimmins E., Vasunilashorn S., Kim J.K., Alley D. Biomarkers related to aging in the human population. Adv Clin Chem 2008, 46:161-216.
21. Gurven M., Kaplan H., Winking J., Finch C., Crimmins E.M. Aging and inflammation in two epidemiological worlds. J Gerontol A Biol Sci Med Sci 2008, 63(2):196-201.
22. Extermann M., Hurria A. Comprehensive geriatric assessment in older patients with cancer. J Clin Oncol 2007, 25:1824-1831.
23. Luciani A., Ascione G., Bertuzzi C., Marussi D., Codecà C., Di Maria G., et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 2010, 28(12):2046-2050.
24. Brunello A, Sandri R, Extermann M. Multidimensional geriatric evaluation of the older cancer patient as a clinical and a research tool. Cancer Treat Rev 2009;35(6):487-92.
25. Störk S., Feelders R.A., van den Beld A.W., Steyerberg E.W., Savelkoul H.F., Lamberts S.W., et al. Prediction of mortality risk in the elderly. Am J Med 2006, 119(6):519-525.
26. Carey E.C., Covinsky K.E., Lui L.Y., Eng C., Sands L.P., Walter L.C. Prediction of mortality in community-living frail elderly people with long-term care needs. J Am Geriatr Soc 2008, 56(1):68-75.
27. Extermann M., Boler I., Reich R., et al. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: design and validation. ASCO national conference 2010, 9000. [Abstr9000].
28. Hurria A., Togawa K., Mohile S.G., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. ASCO Proc 2010, 9001. [Abstr9001].
29. Extermann M. Interactions of cancer and comorbidity. Cancer Control 2007, 14:13-22.
30. Kulminski A.M., Ukraintseva S.V., Kulminskaya I.V., Arbeev K.G., Land K., Yashin A.I. Cumulative deficits better characterizes susceptibility to death in elderly people than phenotypic frailty. Lessons from the Cardiovascular Health Study. J Am Ger Soc 2008, 56:898-903.
31. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer treatment and disease progression J Clin Oncol 2010;28:4086-93.
32. Klepin H., Mohile S., Hurria A. Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw 2009, 7(2):226-236.
33. Inouye S.K., Studenski S., Tinetti M.E. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007, 55(5):780-791.
34. PACE participants. Shall we operate? Preoperative assessment of elderly cancer patietiens (PACE) can help. A SIOG surgical taskforce prospective Study. Crit Rev Oncol Hematol 2008;65:156-63.
35. Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006, 295(7):801-808.
36. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and performance status are independent in older cancer patients. J Cin Oncol 1998, 16:1582-1587.
37. Ingram S.S., Seo P.H., Martell R.E., Clipp E.C., Doyle M.E., Montana G.S., et al. Comprehensive assessment of elderly cancer patients: the feasiblility of self-report methodology. J Clin Oncol 2002, 20:770-775.
38. Repetto L., Fratino L., Audisio R.A., Venturino A., Gianni W., Vercelli M., et al. Comprehensive Geriatric assessment adds information to Eastern Cooperative Group Performance Status in elderly cancer patients: an Italian Group for geriatric Oncology Study. J Clin Oncol 2002, 15:494-502.
39. Manton K.G., Gu X., Lowrimore G.R. Cohort changes in active life expectancy in the U.S. elderly population: experience from the 1982-2004 National Long-Term Care Survey. J Gerontol B Psychol Sci Soc Sci 2008, 63(5):S269-S281.
40. Lattouf J.B., Saad F. Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr Opin Urol 2010, 20(3):247-252.
41. Balducci L., Hardy C.L., Lyman G.H. Hemopoiesis and aging. Biological basis of geriatric oncology 2005, 111-134. Springer, New York. L. Balducci, M. Extermann (Eds.).
42. Chaves P.H., Xue Q.L., Guralnik J.M., Ferrucci L., Volpato S., Fried L.P., et al. What constitutes normal hemoglobin concentration in community-dwelling disabled older women?. J Am Ger Soc 2004, 52:1811-1816.
43. Chaves P.H., Ashar B., Guralnik J.M., Fried L.P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated?. J Am Ger Soc 2002, 1527-1564.
44. Penninx B.W., Pahor M., Cesari M., Corsi A.M., Woodman R.C., Bandinelli S., et al. Anemia is associated with disability and decreased physical perdormance and muscle strength in the elderly. J Am Geriatr Soc 2004, 52:719-724.
45. Ania B.J., Suman V.J., Fairbanks V.F., Melton J.L. Prevalence of anemia in medical practice: Community versus referral patients. Mayo Clin Proc 1994, 69:730-735.
46. Imelmen E.M., D'Alessio M., Gatto M.R., Baggio M.B., Jimenez G., Bizzotto M.G., et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people at home: some results of an Italian Multicentric Study. Aging (Milano) 1994, 6:81-89.
47. Beghe C., Wilson A., Ershler W.B. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med 2004, 116(suppl. 7A):3S-10S.
48. Izaks G.J., Westendorp R.G.J., Knook D.L. The definition of anemia in older persons. JAMA 1999, 281(18):1714-1717.
49. Kikuchi M., Inagaki T., Shinagawa N. Five-year survival of older people with anemia: variation with hemoglobin concentration. J Am Ger Soc 2001, 49:1226-1228.
50. Anía B.J., Suman V.J., Fairbanks V.F., Rademacher D.M., Melton J.L. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 1997, 45(7):825-831.
51. Yamada M., Wong F.L., Suzuki G. RERF's (Radiation Effects Research Foundation) Adult Health Study. Longitudinal trends of hemoglobin levels in a Japanese population-RERF's Adult Health Study subjects. Eur J Haematol 2003, 70(3):129-135.
52. Nilsson-Ehle H., Jagenburg R., Landahl S., Svanborg A. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 2000, 65(5):297-305.
53. Ferrucci L., Guralnik J.M., Woodman R.C., Ershler W.B., Bandinelli S., Patel K.V., et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005, 118(11):1288.
54. Ferrucci L., Semba R.D., Guralnik J.M., Ershler W.B., Bandinelli S., Patel K.V., et al. Pro-inflammatory status, aging, and anemia in older persons. Blood 2010, 115(18):3810-3816.
55. Ferrucci L., Guralnik J.M., Bandinelli S., Semba R.D., Lauretani F., Corsi A., et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol 2007, 136(6):849-855.
56. Dharmarajan T.S., Banik P., Kanagala M., Scarpa J., Norkus E.P. High prevalence of chronic kidney disease, anemia, and falls in an urban long-term care facility: relationship or coincidence. J Am Med Dir Assoc 2010, 11(4):297-299.
57. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
58. Stabler S.P. Prevalence and mechanisms of B12 deficiency. Blood Disorders in the elderly. Cambridge University Press 2008, 181-191. L. Balducci, W.H. Ershler, G. DeGaetano (Eds.).
59. Ferrucci L., Maggio M., Bandinelli S., Basaria S., Lauretani F., Ble A., et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006, 166(13):1380-1388.
60. Halfdanarson T.R., Kumar N., Li, Phyliky R.L., Hogan W.J. Hematological manifestations of copper deficiency. A retrospective review. Eur J Haematol 2008, 80:523-531.
61. Rimon E., Levy S., Sapir A., Gelzer G., Peled R., Ergas D., et al. Diagnosis of iron deficiency anemia in elderly patients by transferrin receptor/ferritin index. Arch Int Med 2002, 162:445-449.
62. Theurl I., Aigner E., Theurl M., Nairz M., Seifert M., Schroll A., et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficient anemia: diagnostic and therapeutic implications. Blood 2009, 113:5277-5286.
63. Denny S.D., Kuchibhatla M.N., Cohen H.J. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 2006, 119(4):327-334.
64. Landi F., Russo A., Danese P., Liperoti R., Barillaro C., Bernabei R., et al. Anemia status, hemoglobin concentration, and mortality in nursing home older residents. J Am Med Dir Assoc 2007, 8(5):322-327.
65. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PH, Newman AB, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005;165(19):2214-20.
66. Culleton B.F., Manns B.J., Zhang J., Tonelli M., Klarenbach S., Hemmelgarn B.R. Impact of anemia on hospitalization and mortality in older adults. Blood 2006, 107(10):3841-3846.
67. den Elzen W.P., Willems J.M., Westendorp R.G., de Craen A.J., Assendelft W.J., Gussekloo J. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. CMAJ 2009, 181(3-4):151-157.
68. Ratain M.J., Schilsky R.L., Choi K.E., Guarnieri C., Grimmer D., Vogelzang N.J., et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989, 45:226-233.
69. Silber J.H., Fridman M., Di Paola R.S., Erder M.H., Pauly M.V., Fox K.R., et al. First-cycle Blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy. J Clin Oncol 1998, 16:2392-2400.
70. Extermann M., Chen A., Cantor A.B., Corcoran M.B., Meyer J., Grendys E., et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J cancer 2002, 38:1466-1473.
71. Schijvers D., Highley M., De Bruyn E., Van Oosterom A.T., Vermorken J.B., et al. Role of red blood cell in pharmakinetics of chemotherapeutic agents. Anticancer Drugs 1999, 10:147-153.
72. Marcantonio E.R., Flacker J.M., Michaels M., Resnick N.M. Delirium is independently associated with poor functional recovery after hip fracture. J Am Ger Soc 2000, 48:618-624.
73. Wu W.C., Rathore S.S., Wang Y., Radford M.J., Krumholz H.M. Blood transfusions in elderly patients with acute myocardial infarction. N Engl J Med 2001, 345:1230-1236.
74. Pickett J.L., Theberge D.C., Brown W.S., Schweitzer S.U., Nissenson A.R. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999, 33(6):1122-1130.
75. Jacobsen P.B., Garland L.L., Booth-Jones M., Donovan K.A., Thors C.L., Winters E., et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004, 28:7-18.
76. Peters R., Burch L., Warner J., Beckett N., Beckett N., Poulter R., et al. Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008, 8:18.
77. Pandya N., Bookhart B., Mody S.H., Funk Orsini P.A., Reardon G. Study of anemia in long-term care (SALT): prevalence of anemia and its relationship with the risk of falls in nursing home residents. Curr Med Res Opin 2008, 24(8):2139-2149.
78. Dharmarajan T.S., Avula S., Norkus E.P. Anemia increases risk for falls in hospitalized older adults: an evaluation of falls in 362 hospitalized, ambulatory, long-term care, and community patients. J Am Med Dir Assoc 2007, 8(3 Suppl. 2):e9-e15.
79. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008, 100(16):1155-1166.
80. Dy S.M., Lorenz K.A., Naeim A., Sanati H., Walling A., Asch S.M. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008, 26(23):3886-3895.
81. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 2000, 5:353-360.
82. Xue Q.L., Bandeen-Roche K., Varadhan R., Zhou J., Fried L.P. Initial Manifestations of frailty criteria and the development of frailty phenotype in the Women Health and Aging Study II. J Gerontol Med Sci 2008, 63:984-990.
83. Hardy S.E., Studenski S.A. Fatigue and function over 3 years among older adults. J Gerontol Biol Sci Med Sci 2008, 63:1389-1392.
84. Hardy SE; Studenski SA. Fatigue predicts mortality in older adults. J Am Ger Soc 2008;56:1910-4.
85. Harris JD. Fatigue in chronically ill patients Curr Opin Supp Palliat Care 2008;2:180-6.
86. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., Einhorn L.H. Clincal evaluation of once weekly dosing of epoietin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J Clin Oncol 2001, 19:2875-2882.
87. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19(11):2865-2874. Epoetin Alfa Study Group.
88. Witzig T.E., Silberstein P.T., LoPrinzi C.L., Sloan J.A., Novotny P.J., Mailliard J.A., et al. Phase III, randomized, double blind study of epoietin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2004, 23(12):2606-2617.
89. Smith R. Application of darbepoietin-alpha, a novel erythropoiesis - stimulating protein, in oncology. Current Opin Hematol 2002, 9:228-233.
90. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299(8):914-924.
91. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., et al. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009, 3:CD007303. Review.
92. Ludwig H., Crawford J., Österborg A., Vansteenkiste J., Henry D.H., Fleishman A., et al. Pooled analysis of individual patient-level data from all randomized, double-blind. Placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009, 27(17):2838-2847.